Home
>
Dana Farber Research
>
Clinical Trials:
Participating Institutions
Current Trials
Pending Trials
Corollary Studies
Recently Completed Trials
Read The Latest WMP
Program News >>
Email this page to a friend >
All of the trials listed below are currently available at our clinic at the Dana-Farber Cancer Institute in Boston as well as at a number of
participating institutions
.
Phase I/II Combination of Everolimus (RAD001), Rituximab (Rituxan) OR Everolimus, Bortezomib (VELCADE, PS-341) and Rituximab in Patients with Relapsed and/or Refractory Waldenstrom's Macroglobulinemia Based on Risk Stratification
Phase-1: Pomalidomide, Dexamethasone and Rituximab in Waldenstrom's Macroglobulinemia
Phase-2: Everolimus (RAD001) in Primary Therapy of Waldenstrom's Macroglobulinemia
Phase-2: LBH589 in Relapsed or Relapsed and Refractory Waldenstrom's Macroglobulinemia
Legal Statements
|
Privacy Policy
